MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'abl'. Sat, 03 Sep 2011 03:34:53 +0100 http://www.medworm.com/index.php?rid=3816657&cid=t_358280_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F08%2F03%2Flargest-study-matching-genomes-to-potential-anticancer-treatments-releases-initial-results%2F The largest study to correlate genetics with response to anticancer drugs released its first results on July 15. The researchers behind the study, based at Massachusetts General Hospital Cancer Center and the Wellcome Trust Sanger Institute, describe in this initial dataset the responses of 350 cancer samples (including ovarian cancer) to 18 anticancer therapeutics. U.K.–U.S. [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3816657 Wed, 04 Aug 2010 03:43:59 +0100 3816657 http://www.medworm.com/index.php?rid=2279375&cid=t_358280_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2009%2F03%2F18%2Fat-9283%2F Astex’s unpartnered JAK/Aur/Abl Ph1b nib poster, clinic Posted in Astex, Aurora, bcr abl, JAK (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=2279375 Thu, 19 Mar 2009 00:30:06 +0100 2279375 http://www.medworm.com/index.php?rid=1055785&cid=t_358280_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2007%2F11%2F28%2Fsome-highlights%2F GSK’s been looking at Plk1 for quite a while. Sure the structure was in an earlier application (March), but here it is better late then never. See: WO/2004/074244, WO/2004/087652, WO/2005/019193, WO/2007/030361, US20070010668, & US20070270437 AP-24534 In here? Earlier Ariad had a double bond wiggling around T315I, in WO/2007/133560 & WO/2007/133562 it’s a triple bond. And Vertex has an interesting series of series of Rock inhibitors in WO/2007/133622. Ki is reported to be <100 nM and clean across the cyps. Oh yah, and if your curious about Cyclacel’s Aurora inhibitor CYC-116, they’ve narrowed it down to 1 of 3 for you and they also give an in vitro panel in WO/2007/132220, WO/2007/132221, WO/2007/132228. The claims make it look like the morpholine. (Sourc... KinasePro blogs http://www.medworm.com/rss/comments.php?id=1055785 Wed, 28 Nov 2007 06:27:15 +0100 1055785 http://www.medworm.com/index.php?rid=883870&cid=t_358280_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2007%2F09%2F18%2Fpdb-update-27%2F Big week 2QOH; PPY-A bound to Abl via Ariad; Chem Biol Drug Des 2Z60; PPY-A bound to T315I Abl (compounds from SGX) 2OH4; Benzimidazole bound to VEGF via GSK JP; J Med Chem 2V7A; PHA-739358 bound to T315I mutant of Abl via Nerviano; Cancer Res 2IN6 Wee1 2IO6 Wee1 (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=883870 Wed, 19 Sep 2007 02:50:05 +0100 883870 http://www.medworm.com/index.php?rid=853126&cid=t_358280_87_f&fid=34865&url=http%3A%2F%2Fwww.thecancerblog.com%2F2007%2F09%2F09%2Fst-jude-finds-factors-that-indicate-resistance-in-acute-lymphob%2F Filed under: LeukemiaResults of a study at St. Jude show why imatinib (Gleevec) is unable to prevent the relapse of an aggressive form of acute lymphoblastic leukemia (ALL). Imatinib has improved the treatment of chronic myelogenous leukemia (CML) dramatically. CML and an aggressive form of ALL share the same mutation, the Philadelphia chromosome (Ph). Ph-postiive cells produce a growth-promoting enzyme BCR-ABL. However, in some aggressive cases of ALL, Ph-positive cells lack a tumor suppressor gene called Arf, which is present in CML cells, say the researchers. The paper's first author, Richard T. Williams, says that doctors might be able to identify those people with ALL who lack Arf.Permalink | Email this | Linking Blogs | Comments (Source: The Cancer ... The Cancer Blog blogs http://www.medworm.com/rss/comments.php?id=853126 Sun, 09 Sep 2007 04:00:00 +0100 853126 http://www.medworm.com/index.php?rid=789373&cid=t_358280_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2007%2F08%2F09%2Fls-104%2F The news today is that LS-104 is in Ph1 and now owned by Aegera from Lymphosign who in turn licsensed it from HSC. Their portfolio of patent applications suggests the compound is likely a tyrphostin derivative. LS104 is a novel small molecule tyrosine kinase inhibitor of therapeutically significant kinases including Jak2 and Bcr-Abl…In contrast to marketed kinase inhibitor drugs, LS104 inhibits its targets in a non-ATP-competitive manner WO/2005/092904 I don’ t know about you but I needed a history lesson to get a handle on these… (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=789373 Thu, 09 Aug 2007 04:44:33 +0100 789373 http://www.medworm.com/index.php?rid=734015&cid=t_358280_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2007%2F07%2F13%2Ftargagen-closes%2F Closes a 40M series D that is. Kudos Pros. Some of the more recent thiazole apps like US20070161645 appear to my eye to be the Src/Abl backup brigade. wt Abl 1.5 nM T315I 18 nM So you like pictures? (more…) (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=734015 Fri, 13 Jul 2007 08:18:30 +0100 734015